Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 24c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.57), $0.24 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.9 million versus the consensus estimate of $65.88 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings
• BWS Financial Starts Capstone Energy Plus (CEPL) at Buy